Selank

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) built by extending the immunoglobulin-derived tetrapeptide tuftsin with a Pro-Gly-Pro tail that resists enzymatic degradation. The proposed mechanism is multimodal rather than single-receptor. Published work has documented allosteric modulation of GABA-A receptor sensitivity, reshaping of GABA-induced gene-expression patterns in human IMR-32 neuroblastoma cells (Selank alone produced no baseline mRNA changes — its effect appeared only in combination with GABA or olanzapine; [Filatova et al., *Front Pharmacol* 2017, 8:89](https://doi.org/10.3389/fphar.2017.00089)), elevated brain-derived neurotrophic factor (BDNF) in rat hippocampus, and modulation of leu-enkephalin turnover in human plasma. Unlike benzodiazepines, Selank does not appear to bind the benzodiazepine site of the GABA-A receptor directly, which is the hypothesis underlying its reported non-sedating, non-dependency-forming profile. In Russian clinical use it is administered intranasally; subcutaneous and intravenous routes appear in the experimental rodent literature.

Selank has a deeply asymmetric evidence base, and that asymmetry is the central honest fact about this peptide. It has been used in Russian psychiatric practice since approval in 2009 for generalized anxiety disorder and neurasthenia, and the underlying program at the Russian Academy of Medical Sciences spans roughly three decades. In the West it is essentially unknown in clinical practice and almost entirely unstudied at the standards used by the FDA or EMA for approval. The peer-reviewed Western literature on Selank is real but thin, and it is heavily weighted toward mechanism rather than clinical efficacy. The single comparative clinical trial readily indexed in English-language databases (Zozulya et al., *Zhurnal Nevrologii i Psikhiatrii* 2008) studied 62 patients with GAD or neurasthenia, comparing Selank (n=30) to medazepam (n=32, a benzodiazepine active comparator). The anxiolytic effect of the two drugs was reported as comparable, with Selank additionally producing antiasthenic and mild psychostimulant effects. Mechanistic work from Western journals — including the 2017 *Frontiers in Pharmacology* paper on Selank's effects on GABA-induced gene expression in the IMR-32 cell line (Filatova et al.) and a 2019 *Bulletin of Experimental Biology and Medicine* paper on Selank-associated BDNF elevation in rat hippocampus — describes a real but quite context-dependent set of effects, not a settled clinical case. That dynamic is what the term *evidence-depth gap* captures here. Most of what is asserted about Selank in English-language wellness writing rests on a Russian clinical literature that has not been independently replicated in Western RCTs and that does not generally meet contemporary FDA or EMA methodological standards. That is not a claim the evidence is wrong; it is a claim the evidence base is parallel to, not overlapping with, the standards used to approve psychiatric drugs in the United States or European Union. Treat Selank as a plausibly useful peptide with thin Western validation — not as a peer-tested anxiolytic on the order of an SSRI or benzodiazepine.